Stock DNA
Pharmaceuticals & Biotechnology
HKD 1,050 Million ()
NA (Loss Making)
NA
1.00%
-0.49
-2.77%
0.43
Revenue and Profits:
Net Sales:
224 Million
(Quarterly Results - Jun 2025)
Net Profit:
3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-21.47%
0%
-21.47%
6 Months
-11.62%
0%
-11.62%
1 Year
5.86%
0%
5.86%
2 Years
17.96%
0%
17.96%
3 Years
-5.86%
0%
-5.86%
4 Years
-28.64%
0%
-28.64%
5 Years
-29.85%
0%
-29.85%
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.28%
EBIT Growth (5y)
-187.22%
EBIT to Interest (avg)
64.58
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.49
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
129.33%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.48%
ROE (avg)
5.95%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.47
EV to EBIT
0.58
EV to EBITDA
-1.81
EV to Capital Employed
-0.03
EV to Sales
-0.06
PEG Ratio
NA
Dividend Yield
0.90%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
224.40
191.20
17.36%
Operating Profit (PBDIT) excl Other Income
15.00
19.30
-22.28%
Interest
0.20
0.20
Exceptional Items
0.00
0.00
Consolidate Net Profit
3.30
2.80
17.86%
Operating Profit Margin (Excl OI)
-33.40%
-15.60%
-1.78%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 17.36% vs 11.62% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 17.86% vs 105.54% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
761.10
934.10
-18.52%
Operating Profit (PBDIT) excl Other Income
80.80
153.70
-47.43%
Interest
0.70
3.50
-80.00%
Exceptional Items
-4.30
-5.60
23.21%
Consolidate Net Profit
42.80
119.80
-64.27%
Operating Profit Margin (Excl OI)
-11.00%
90.90%
-10.19%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -18.52% vs -21.58% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -64.27% vs -24.94% in Dec 2023
About Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd. 
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






